Abstract: Objective To investigate the efficacy of losartan on heart function and uric acid in patients with chronic heart failure (CHF). Methods 85 patients with CHF were divided into two groups randomly. The routine anti-CHF treatment included cardiotonic, diuresis, isosorbide dinitrate, beta-blockers. In losartan group（n=43）, patients were given routine anti-CHF treatment and losartan. However, the patients in control group（n=42） were treated by routine anti-CHF treatment and Benazapril. The heart functional class was evaluated. The content of serum uric acid, electrocardiogram, and Duppler ultransonography were measured before and after treatment in two groups, respectively. Results The variance of heart functional classify, left ventricle diastoic diameter (LVDD), left ventricle ejection fraction (LVEF) and cardiothotic ratio did not show statistical notability between two groups before treament. However, they had been improved sharply compared with base condition in both group after 3 months and 12 months treatment(p﹤0.01) . Although the level of serum uric acid were decreased than base-level in both group after 12 months, but the significant change had shown only in the losartan group (p﹤0.01). Conclusion Losartan is efficacy and safety in the treatment of chronic heart failure with reducing serum uric acid.